Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
eNq1mF9v2jAUxd/5FFEe9kZCaBmwJVQbazekVmO0aNNekEkuxczYqf8A7aefQ+hKJ2ddDX4kNsfXPte/HCU+2yyJtwIuMKOJHwUN3wOasgzT28Qf31zUO/5ZrxYv0Ao9TWvqeUEU+V5KkBCJX4wGU0BUBD+uLj+B/j9wv1fzYjZdQCqfzVMSk+ALEvMrlBdzvHjFcOYtQc5Zlvi5ktunXiwk11X01oz/EjlKIQ53T/ZHF5PT/edxWIj9h6oSwC8RvTWKArXSTBXnQGUfSbhl/L6i3hMrbSxGIJjiKQyRnA85W+EMMuMSM0QEWC0yW2fXwFcEZLGIUTxcpEthJY4WaDOCu4G56A96tC83st6oR+1Ot9tpdduNVsPOXL53VGYX9CbCdBK1m42o2Q6BhkSl2josLM0ZMi4RcWQLFv3nneVoHQ53L9qfYZETdB8sRG57VIgjPQxc3393Gyl2cMM1kYg+s7/0qSIkfGXV4x0vHFVc4KjPFJUV2LgY2R5En1EJm2pH7UgnN7texCCOJ/vAqJnyQzUlOLVlmqaOAiHHo0E10o5Kg49IwJi7w8F3TDO2FsfHzL6tjqrPt6Q0iuY8iybNbudt1GpZ36Kfuocq3jHnirMcQg0gS2d3XBnQGTuUKLotzVKPTXm8ftxGHZYiAhVhp25JF92Ij9nMWau7u0blgFH08/mNbX98U8Dvr7c/jdI4S/44a4deFzzX3fhS4eW9TfLJSaPV6Z6cvkHL/P1jik4sE3Mp6iQwK26GzFzKXLwLw/V6HcyRqAukzzOY8X+8Bc6Mez/G/jVyn+x0F+qdZIAyE5W4dVT6tHyPvs5H25v7Uko4NPnu/r9L2MY1JFdwgBcl5J2heHB+fLo/xV5nZQ+fMcbdMtuIiiRm1FVyUlOj4mHvE+0rveAaEF9nM1zxkaWyL+Ow/MDTq8Vh8XGnV/sNDB0CHA==
uL6fwCE7TFQcQyc1
